Abstract
Glioma is the most common primary intracranial tumor and is associated with very low survival rates. The development of reliable biomarkers can help to elucidate the molecular mechanisms involved in glioma development. Here the expression of ABCC8 mRNA, clinical characteristics, and survival information based on 1893 glioma samples from four independent databases were analyzed. The expression patterns of ABCC8 mRNA were compared by a Chi square test. The overall survival rate of gliomas was evaluated according to the expression level of ABCC8 mRNA. The prognostic value of this marker in gliomas was tested using Cox single factor and multi factor regression analyses. We found patients with low WHO grade, oligodendrocytoma, low molecular grade, IDH mutation, and 1p19q combined deletion had high ABCC8 mRNA expression. The patients with high expression of ABCC8 mRNA had longer survival. ABCC8 mRNA expression was a new independent prognostic index for glioma. Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8 mRNA expression glioma patients, whereas in patients with low expression, there was no significant difference. So ABCC8 mRNA expression could be an independent prognostic indicator for glioma patients and could predict the sensitivity of glioma to temozolomide.
Highlights
Glioma is the most common primary intracranial tumor and is associated with very low survival rates
ABCC8 mRNA expression was higher in patients with better prognosis indicators, such as oligodendroglioma, low World Health Organization (WHO) grade, IDH mutation, 1p/19q col-deletion and low WHO molecular grade (2016) (Table 1)
The results showed that ABCC8 mRNA expression was higher in patients with better prognosis indicators, such as oligodendroglioma (p = 1.4e−32), low WHO grade (p = 2.5e−23), IDH mutation (p = 6.4e−20), 1p/19q col-deletion (p = 7.3e−23) and low who molecular grade (2016) (p = 2.8e−35)
Summary
Glioma is the most common primary intracranial tumor and is associated with very low survival rates. The expression of ABCC8 mRNA, clinical characteristics, and survival information based on 1893 glioma samples from four independent databases were analyzed. The overall survival rate of gliomas was evaluated according to the expression level of ABCC8 mRNA. Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8 mRNA expression glioma patients, whereas in patients with low expression, there was no significant difference. We collected the expression data and clinical information with respect to ABCC8 mRNA based on 656 glioma samples from CGGA database as testing set. The expression patterns of ABCC8 in different types of gliomas were compared and the overall survival (OS) rate of glioma patients was evaluated according to the expression level of ABCC8 mRNA, and the prognostic value of this marker in gliomas was tested.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
